106 results
8-K
NAMS
NewAmsterdam Pharma Company NV
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:15pm
the appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the Company’s annual accounts … of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 by the audit committee … the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company
Proposal 5 Appointment of William H. Lewis
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
and timely conduct of our clinical trials;
obtain and maintain investigational review board (“IRB”) or independent ethics committee (“EC") approval … with more extensive product lines;
unforeseen costs and expenses associated with creating an independent sales and marketing organization
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 by the audit committee … the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company
Proposal 5 Appointment of William H. Lewis
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
to, an exemption from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002 requiring that the Company’s independent registered public … ended December 31, 2023, incorporated by reference into this prospectus, have been audited by Deloitte Accountants B.V., an independent registered public
POS AM
EX-23.3
r5d2jdiwi7fmwxiw
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
POS AM
vuh18yr
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
POS AM
EX-5.1
t68mnvh ypb
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
424B3
2ujf wgwo00
12 Mar 24
Prospectus supplement
4:18pm
POS AM
l95fjvkiid
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
POS AM
EX-23.3
h95 uw0g41s
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
POS AM
EX-5.1
43r15x3epndoq
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
fk6o aa2iy1
28 Feb 24
Annual report
8:00am
10-K
EX-97.1
i189vhw wm
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
mii7y7c14k1anmvo z1
28 Feb 24
Annual report
8:00am
10-K
EX-23.1
nvej pb63x
28 Feb 24
Annual report
8:00am
10-K
EX-10.4
9a81f 10lf6pl8j6
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
gysq8lf408av
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
8-K
EX-5.1
3uglq8th3wl
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
l548h7ocv5ge 8j0r5u
15 Feb 24
Prospectus supplement for primary offering
4:15pm